A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Clinical trial NCT04434196 · COMPLETED
Trial details
- NCT number
- NCT04434196
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-21
- Primary completion
- 2024-05-21
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.